From diagnostic findings to an anatomic map.

Cancer mapping brings imaging, spatially identified pathology and other diagnostic findings together within the anatomy of the prostate.

BioVantra integrates these inputs to estimate the location and extent of disease, preserving the relationship between what was found and where it was found.

Sagittal anatomic map of the prostate showing an estimated tumor volume within the gland, with surrounding margin and negative systematic biopsy sites marked.

Bringing the findings back together.

Cancer mapping depends on preserving spatial relationships throughout the diagnostic pathway.

Imaging

Establishes the anatomic reference and identifies imaging-defined suspicious disease.

Spatial pathology

Connects diagnosis, grade and measured tumor involvement with the recorded locations from which tissue was obtained.

Cytomolecular findings

Add cellular and molecular observations from defined regions of the prostate when available.

Read together, these findings provide more information than any one component alone.

Axial, sagittal and coronal T2 MRI images of the prostate with a left posterolateral peripheral zone lesion indicated at the mid gland. — Multiplanar T2 MRI establishing the initial spatial reference.

Estimating location and extent.

The integrated map relates diagnostic findings to prostate anatomy to estimate where cancer is present and how far the identified disease may extend.

Imaging-defined lesions provide the initial spatial reference. Biopsy findings establish disease at known sampled locations, while measured tumor involvement and additional spatially identified findings refine the estimate of disease distribution.

The result is an anatomic representation of the estimated cancer volume—not simply a list of positive biopsy sites.

From tumor estimate to treatment margin.

For spatially targeted therapy, the estimated tumor volume can be considered together with a planned treatment margin.

Margin visualization extends beyond the estimated disease boundary to provide an anatomic reference that the treating physician can consider alongside the selected treatment modality, surrounding structures and other clinical information.

Sagittal anatomic map with a legend identifying the estimated tumor volume, a 10 mm therapeutic margin, a planned cryotherapy ablation zone and negative systematic biopsy sites. — Estimated tumor volume shown with a planned therapeutic margin within prostate anatomy. Treatment modality and margin are determined by the treating physician.

Designed to support spatially targeted treatment planning.

The mapping output is intended to provide the treating physician with an integrated spatial representation of the diagnostic findings.

When focal or targeted therapy is being considered, the map can be reviewed alongside the original imaging, pathology, clinical findings and the technical requirements of the selected treatment.

Preserving the connection between diagnosis and anatomy helps translate diagnostic information into a spatial framework for treatment planning.